|
Levamisole-containing anthelmintic medicine Decaris, tablets 50 mg and 150 mg will no longer be available on the market due to risk of leukoencephalopathy
|
|
Remsima (infliximab) - patient reminder card
|
|
CellCept (Mycophenolate mofetil), new important identified risk
|
|
Salbutamol (metered-dose inhaler)
|
|
Tecentriq (atezolizumab) and Avastin (bevacizumab): Atezolizumab in combination with bevacizumab is NOT approved as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation and the benefit-risk profile does not support the use of atezolizumab plus bevacizumab in this setting
|
|
Actemra (tocilizumab)
|
|
Guide for doctors with information on the use of the drug Rufixalo (rivaroxaban)
|
|
Integrilin (eptifibatide)
|
|
Lefluonia
|
|
Tecentriq (atezolizumab)
|
